TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00004689
Drug: streptomycin
Normalized name: Streptomycin
DrugBank: Streptomycin (DB01082)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01359228
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 tablet three times a day for 14 days.
Study: NCT01904695
Drug: Herbs
Normalized name: HERBS/ALTERNATIVE THERAPIES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbs 180ml by mouth every 12 hours for 8 weeks
Study: NCT01750905
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (D5W) SQ
Study: NCT03803436
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX
Study: NCT03803436
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panitumumab
Study: NCT01904695
Drug: Antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide diuretics and ACE inhibitor and β-blocker in different dosage determined by the physician for 8 weeks
Study: NCT02242383
Drug: Telmisartan in combination with hydrochlorothiazide
Normalized name: hydrochlorothiazide / telmisartan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01793883
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003569
Drug: dimesna
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00525096
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets twice a day per os
Study: NCT00525096
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2\*200 mg tablets twice a day per os
Study: NCT03154749
Drug: DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All eligible patients were randomly assigned at a 1:1 ratio to the experimental arm (docetaxel (75 mg/m2 administered intravenously every 3 weeks) plus carboplatin (AUC 6 mg/mL per min, intravenously every 3 weeks) for six cycles) or the standard treatment arm (epirubicin (90 mg/m2) plus cyclophosphamide (600 mg/m2), both administered intravenously every 3 weeks for four cycles, followed by docetaxel (100 mg/m2) administered intravenously every 3 weeks for four cycles).
Study: NCT03433352
Drug: Propylthiouracil Pill
Normalized name: propylthiouracil Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who developed GD received propylthiouracil treatment
Study: NCT02872272
Drug: Treatment with Amikacin
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Aminoglycosides. Blood sampling for pharmacokinetic evaluation
Study: NCT00486824
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 50 mg tablet of Indomethacin plus 2 pills of placebo followed by one 25 mg tablet of oral indomethacin every 6 hrs for 48 hrs.
Study: NCT00411814
Drug: GSK679586
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Drug
Study: NCT00411814
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline
Study: NCT03252002
Drug: BAY1101042
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or optionally 5 mg BAY 1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
Study: NCT03252002
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose on Day 1 (00d) and once daily for 7 days from Day 3 (02d) until Day 9 (08d)
Study: NCT01835730
Drug: PE0139 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01835730
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00659230
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-800mg placebo
Study: NCT00669383
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IM q 24 hours x 2 doses
Study: NCT01185977
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one-week single-blind PBO-lead-in phase, FLX 10 mg/d for 4 days then 20 mg/d of FLX thereafter
Study: NCT01185977
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One pill of PBO for 4 days then two pills of PBO thereafter
Study: NCT02687100
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive 8 mL of saline without any drug
Study: NCT00507000
Drug: Lactose granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Lactose placebo Lactose placebo granules in identical sachet given weekly and two lactose tablets for first two months followed one sachet of placebo granules every month and two tablets of lactose containing placebo tablets taken daily for next four months
Study: NCT01105273
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg IV on day-3 and -2
Study: NCT00226395
Drug: Oxymorphone immediate release
Normalized name: oxymorphone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00729937
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg, four times per day.
Study: NCT00743366
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00102284
Drug: levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01397838
Drug: Pro-Bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg Capsules of Pro-Bone twice daily
Study: NCT01992211
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.
Study: NCT01992211
Drug: BCWP_C003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant will be administered a single oral dose of BCWP_C003 under Fasting condition or Fed condition according to sequence.
Study: NCT01268527
Drug: 0.1% E6201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
Study: NCT01268527
Drug: 0.2% E6201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.2% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
Study: NCT01268527
Drug: 0.005% E6201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.005% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
Study: NCT01268527
Drug: 0.01% E6201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.01% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
Study: NCT01192568
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel
Study: NCT01251835
Drug: Sitaxsentan alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days 1-5: Sitaxsentan tablet, 100 mg, q24 h (once a day)
Study: NCT01492075
Drug: PCRA (Intermittent injection)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent injection of LA intraabdominally
Study: NCT02100969
Drug: HIZENTRA ®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients must fulfill inclusion criteria and remain stable at week 0, which means QMG does not increase by 3 points, will enter receive Hizentra for 12 weeks.
Study: NCT01268527
Drug: 0.05% E6201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.05% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
Study: NCT00765674
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT00765674
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules
Study: NCT02516592
Drug: QVA149 110/50 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVA149 110/50 micrograms o.d. capsules for inhalation, supplied in blisters via a single dose dry powder inhalater (SDDPI)
Study: NCT02411565
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried and pulverized, white and black rice, 5.53 grams, combined with natural orange flavor and stevia Reb-A sweetener, to create an instant drink mix, dissolved in 150 mL of water, orally once-daily, for 2 to 4 weeks.
Study: NCT00913484
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram 250 mg per day
Study: NCT00913484
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily
Study: NCT02806375
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day +3 and +4: 50 mg/kg/day iv qd
Study: NCT03479320
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative anlagesic requirements will be calculated and compared with experimental group
Study: NCT02053818
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomization to receive Remifentanil (ultrashort acting opioid) as basic opioid in anaesthesia
Study: NCT02053818
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomization to receive Sufentanil (medium/long acting opioid) as basic opioid in anaesthesia
Study: NCT03298646
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg Diclofenac oral tablet one hour before the procedure.
Study: NCT01913418
Drug: Suan-Zao-Ren Tang placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Suan-Zao-Ren Tang placebo granules are prepared with 4 g starch inside the same colored and sized foil packages.
Study: NCT02644187
Drug: BF200-ALA/5-aminolevulinic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prodrug applied to whole treatment area previous to illumination with either light source.
Study: NCT01384994
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg/m2, 2h infusion, d1, q2w
Study: NCT01384994
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg/m2, 2-h infusion, d1, q2w
Study: NCT02271958
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01298999
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo: one capsule to be taken by mouth once daily for 12 weeks.
Study: NCT01338025
Drug: HAART regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study participant continued their non-suppressive HAART regimen as prescribed by their primary provider.
Study: NCT01461876
Drug: antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care antiretroviral therapy
Study: NCT02223923
Drug: AZD6738
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03954444
Drug: Rhofade Cream, 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference Comparator
Study: NCT03954444
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT00636649
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00808379
Drug: Chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy will begin on the first day of radiotherapy and continue until the completion of radiotherapy. Capecitabine will be administered orally daily 2000 mg/m2 in two divided doses (approximately 12 hours apart) for 2 weeks followed by a 1-week rest period given as 3 week cycles.
Study: NCT00976599
Drug: CP-690,550 + methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-690,550 dose is 10 mg twice daily, oral tablets, for 4 weeks Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week
Study: NCT00976599
Drug: Placebo + Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week
Study: NCT03464968
Drug: Oxaliplatin,5FU, leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX
Study: NCT03464968
Drug: irinotecan,5FU, leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFIRI
Study: NCT03696290
Drug: Aztreonam lysine
Normalized name: aztreonam lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised aztreonam lysine 75mg
Study: NCT01263808
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD via SDDPI
Study: NCT02238834
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive single doses of FP-025 matching placebo (capsule) in a dose escalation format.
Study: NCT02238834
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive FP-025 matching placebo (capsule) twice daily for 5 days
Study: NCT01654640
Drug: Placebo (for metformin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 1T bid
Study: NCT04790292
Drug: group MD
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg morphine + 8mg dexamethasone completed to 5 ml with normal saline + 10 ml of 0.25% bupivacaine (total volume of 15ml) were injected intra-articularly
Study: NCT00122655
Drug: non-nucleoside reverse transcriptase inhibitors
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00122655
Drug: nucleoside reverse transcriptase inhibitors
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00122655
Drug: protease inhibitors
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02175914
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Treatment with Erythromycin 500mg, twice daily, for 12 weeks
Study: NCT00964561
Drug: Placebo Antibiotic and Valortim
Normalized name: beclometasone and antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days 1-3 20mg/kg IV Normal Saline BID over 60 minutes. Day 4 20mg/kg Valortim IV over 60 minutes.
Study: NCT02619032
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative continuous infusion of remifenatanil. Remifentanil infusion was interrupted upon completion of surgical intervention.
Study: NCT02619032
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 50 μg iv bolus at the induction of anesthesia and before the start of surgery.
Study: NCT03162458
Drug: Anaferon for children (liquid dosage form)
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.
Study: NCT03777319
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone will be prescribed for 6 months, after which the family and primary care physician will determine to either remain on spironolactone or transfer to prednisolone.
Study: NCT03777319
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone will be prescribed for 6 months as the clinical standard of care.
Study: NCT01238328
Drug: Conditioning regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: For sibling full match:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* Antithymocyte globulin (ATG) rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg~For haploidentical:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* Fludarabine 160 mg/m\^2
Study: NCT00304863
Drug: Lactobacillus GG
Approvals — FDA: no, EMA: no, PMDA: no
Description: This arm will receive the additional probiotic of lactobacillus GG
Study: NCT03813992
Drug: MED2005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Product
Study: NCT00992823
Drug: iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 doses of 30 mg of ferrous sulfate during a 10-month intervention period
Study: NCT01622777
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg daily of oral rosuvastatin for 12 weeks
Study: NCT01622777
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of oral placebo with identical appearance, form and size than rosuvastatin, one tablet daily for 12 weeks
Study: NCT03033264
Drug: Dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg of a Dinoprostone vaginal insert.
Study: NCT02481310
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02481310
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02481310
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT or intraventricularly
Study: NCT02481310
Drug: Therapeutic Hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IT or intraventricularly
Study: NCT02832596
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ordinary anaesthesia and maintained preanesthetic blood pressure by norepinephrine infusion
Study: NCT00109291
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04197986
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomly assigned to placebo will receive placebo matching in appearance the investigational product (infigratinib), which will be provided as hard gelatin capsules for oral use and will be administered once daily on a 3 weeks on (Days 1-21) /1 week off (Days 22-28) dosing schedule.
Study: NCT01229761
Drug: cotrimoxazole placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg/20mg per day (or 2.5 mL of syrup from a 200mg/40mg per 5mL suspension) from 1-6 months, followed by 200mg/40mg per day (or 5 mL of syrup from a 200mg/40mg per 5 mL suspension) from 6 to 12 months
Study: NCT04569357
Drug: Prospekta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration.
Study: NCT04569357
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration.
Study: NCT00405652
Drug: Enteric-coated Mycophenolate sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: experimental
Study: NCT03845959
Drug: TD0019 oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: TD0019 are green, hard capsule with size 0, containing yellow herbal powder with special smell of herbal.
Study: NCT03845959
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01554800
Drug: ACP-501
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose infusion
Study: NCT02611700
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg,day1,weekly,until disease progression or toxicity
Study: NCT00435994
Drug: Inhaled primatene will be given as a breathing treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: While the research subject is sedated an inhaled mist of primatene mist will be given to the patient.
Study: NCT03096444
Drug: Lipoderm Cream
Normalized name: Lipoderm Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2g of topical vehicle (Lipoderm) will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
Study: NCT03322969
Drug: XELOX/SOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: receiving the original chemotherapy
Study: NCT01752959
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1-0.3 micg/kg/min Remifentanil iv infusion
Study: NCT02633800
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match patritumab
Study: NCT01453907
Drug: ETI-204, Anthim
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenously, single dose
Study: NCT01453907
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenously, single dose
Study: NCT02447809
Drug: acetylsalicylic acid (ASA)
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02557854
Drug: Doxorubicin HCl liposomal injection
Normalized name: DOXORUBICIN HYDROCHLORIDE LIPOSOME
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg IV every 4 weeks
Study: NCT00158223
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug and placebo will be encapsulated in an identical fashion. The placebo capsule will be made to match in appearance and weight. There will be flexible dosing, allowing a minimum of 1 capsule per day to 4 capsules per day, in order to match the dosing range of the active treatment.
Study: NCT02072382
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02261493
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline) injected into the protocol-specified areas on Day 1.
Study: NCT01375348
Drug: Ultiva (remifentanil) or placebo
Normalized name: remifentanil Injection [Ultiva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1microg/kg/min remifentanil administered as infusion Max infusion time is 20min
Study: NCT01413568
Drug: POL6326
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01631630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is an inactive tablet design to look exactly like pioglitazone